- Halozyme Therapeutics (HALO +0.7%) reports that data from the Phase 2 HALO-202 study assessing the combination of PEGPH2 and Celgene's Abraxane (nab-paclitaxel) in pancreatic cancer will be presented at ASCO on June 4 in the am.
- The study showed the combination increased median progression-free survival by 77% compared to chemo alone in stage IV pancreatic cancer patients.
- Previously: Halozyme's lead product candidate shows positive effect in mid-stage pancreatic cancer study; shares ahead 25% premarket (Jan. 5)
Halozyme announces Phase 2 data on PEGH20 in pancreatic cancer to be presented at ASCO
Recommended For You
More Trending News
About HALO Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
HALO | - | - |
Halozyme Therapeutics, Inc. |